CA2671939C - Biomarker for detecting prostate cancer - Google Patents

Biomarker for detecting prostate cancer Download PDF

Info

Publication number
CA2671939C
CA2671939C CA2671939A CA2671939A CA2671939C CA 2671939 C CA2671939 C CA 2671939C CA 2671939 A CA2671939 A CA 2671939A CA 2671939 A CA2671939 A CA 2671939A CA 2671939 C CA2671939 C CA 2671939C
Authority
CA
Canada
Prior art keywords
fragment
seq
sequence homology
prostate cancer
transcription factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2671939A
Other languages
English (en)
French (fr)
Other versions
CA2671939A1 (en
Inventor
Hardev Pandha
Richard George Leonard Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Surrey
Original Assignee
University of Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Surrey filed Critical University of Surrey
Publication of CA2671939A1 publication Critical patent/CA2671939A1/en
Application granted granted Critical
Publication of CA2671939C publication Critical patent/CA2671939C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CA2671939A 2006-12-19 2007-12-19 Biomarker for detecting prostate cancer Active CA2671939C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0625321.5 2006-12-19
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GB0719792.4 2007-10-10
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers
PCT/GB2007/004902 WO2008075056A1 (en) 2006-12-19 2007-12-19 Cancer biomarkers

Publications (2)

Publication Number Publication Date
CA2671939A1 CA2671939A1 (en) 2008-06-26
CA2671939C true CA2671939C (en) 2017-10-03

Family

ID=39265269

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2671939A Active CA2671939C (en) 2006-12-19 2007-12-19 Biomarker for detecting prostate cancer

Country Status (19)

Country Link
US (1) US8460882B2 (enExample)
EP (1) EP2115472B1 (enExample)
JP (1) JP5683108B2 (enExample)
CN (1) CN101675341B (enExample)
AU (1) AU2007335999B2 (enExample)
BR (1) BRPI0720371B8 (enExample)
CA (1) CA2671939C (enExample)
CY (1) CY1115178T1 (enExample)
DK (1) DK2115472T3 (enExample)
ES (1) ES2445185T3 (enExample)
GB (2) GB0625321D0 (enExample)
IL (1) IL199241A (enExample)
MX (1) MX2009006378A (enExample)
NZ (1) NZ577548A (enExample)
PL (1) PL2115472T3 (enExample)
PT (1) PT2115472E (enExample)
RU (1) RU2460075C2 (enExample)
SI (1) SI2115472T1 (enExample)
WO (1) WO2008075056A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
MX2012000541A (es) * 2009-07-13 2012-03-14 Univ Surrey Peptidos, polipeptidos y secuencias de acidos nucleicos terapeuticos.
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
AU2012252426A1 (en) * 2011-05-12 2013-11-28 Noviogendix Research B.V. Molecular markers in prostate cancer
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
CN103797120B (zh) * 2011-09-16 2017-04-12 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
MX2014006662A (es) * 2011-12-05 2015-04-16 Phigenix Inc Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.
WO2014005138A1 (en) * 2012-06-29 2014-01-03 Kerschensteiner Daniel A Colorimetric gelatinase assay
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
WO2014179959A1 (en) * 2013-05-09 2014-11-13 The Procter & Gamble Company Method and system for assessing health condition
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) * 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
WO2016193110A1 (en) * 2015-05-29 2016-12-08 Koninklijke Philips N.V. Methods of prostate cancer prognosis
EP3960195B1 (en) * 2015-09-23 2025-01-08 Centre national de la recherche scientifique Engrailed for treatment of amyotrophic lateral sclerosis
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
US10508287B2 (en) 2016-12-28 2019-12-17 Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences Method for regenerating T cells and applications thereof
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777254B1 (ko) 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777259B1 (ko) 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0996725A1 (en) * 1997-06-27 2000-05-03 Human Genome Sciences, Inc. Human nk-3 related prostate specific gene-1
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
JP2002527758A (ja) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
EP1290442B1 (en) 2000-05-30 2013-11-13 Aarhus Universitet An assay method for testing plant material for exposure to herbicides using biomarkers
WO2002000926A2 (en) * 2000-06-30 2002-01-03 Epigenomics Ag Diagnosis of diseases associated with signal transduction
AU2001292718A1 (en) * 2000-09-12 2002-03-26 Transgenetics Incorporated Microarrayed organization of transcription factor target genes
WO2002054936A2 (en) 2000-12-24 2002-07-18 Kohn, Kenneth, I. A method for detecting biomarkers
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
CA2439854A1 (en) * 2001-03-01 2002-09-12 Epigenomics Ag Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
JP5745202B2 (ja) * 2004-12-02 2015-07-08 エピゲノミックス アクチェンゲゼルシャフト 前立腺細胞増殖障害の予後に関連する遺伝子発現分析のための方法および核酸
US9416422B2 (en) 2005-02-18 2016-08-16 Sloan-Kettering Institute For Cancer Research Methods for detecting minimum residual disease

Also Published As

Publication number Publication date
GB0625321D0 (en) 2007-01-24
ES2445185T3 (es) 2014-02-28
MX2009006378A (es) 2009-08-24
NZ577548A (en) 2012-03-30
AU2007335999A1 (en) 2008-06-26
CN101675341B (zh) 2017-08-08
CY1115178T1 (el) 2016-12-14
US20100093558A1 (en) 2010-04-15
DK2115472T3 (da) 2014-02-10
JP2010513901A (ja) 2010-04-30
BRPI0720371B8 (pt) 2021-07-27
BRPI0720371B1 (pt) 2019-05-28
PT2115472E (pt) 2014-02-14
PL2115472T3 (pl) 2014-05-30
EP2115472B1 (en) 2013-11-06
WO2008075056A1 (en) 2008-06-26
GB0719792D0 (en) 2007-11-21
CA2671939A1 (en) 2008-06-26
IL199241A (en) 2014-03-31
EP2115472A1 (en) 2009-11-11
JP5683108B2 (ja) 2015-03-11
BRPI0720371A2 (pt) 2013-12-31
CN101675341A (zh) 2010-03-17
AU2007335999B2 (en) 2013-09-05
RU2009127774A (ru) 2011-01-27
SI2115472T1 (sl) 2014-05-30
US8460882B2 (en) 2013-06-11
RU2460075C2 (ru) 2012-08-27

Similar Documents

Publication Publication Date Title
CA2671939C (en) Biomarker for detecting prostate cancer
EP1800130B1 (en) Methods and compositions for evaluating breast cancer prognosis
EP1996940B1 (en) Detection of cancer by elevated levels of bcl-2
RU2596394C2 (ru) Маркеры для рака эндометрия
US20070218512A1 (en) Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
CN101014862A (zh) 用于检测卵巢疾病的方法和组合物
Chai et al. Discovery of potential serum protein biomarkers for lymph node metastasis in oral cancer
AU2013284448A1 (en) Use of markers in the diagnosis and treatment of prostate cancer
CN110139656A (zh) 作为膀胱癌的生物标志物的角蛋白17
CN101669032A (zh) 通过膜联蛋白a3对前列腺癌症的自身免疫调节
Gerhardt et al. The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro
EP2581745B1 (en) Composition for diagnosis of lung cancer and diagnosis kit of lung cancer
Pei et al. Study on the Expression of S100A4 and HMGA1 in Endometrial Carcinoma and Their Correlation with Metastasis
US7951544B1 (en) Method for determining the prognosis of cancer patients by measuring levels of bag expression
WO2006119264A2 (en) Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
US8703127B2 (en) Methods and materials for the diagnosis of prostate cancers
KR20110088462A (ko) 난소암 진단을 위한 콜라겐 유형 ⅵ 알파 １의 신규한 용도
KR20240161980A (ko) 갑상선암의 진단을 위한 신규한 바이오 마커
Yang et al. BIOM-51. DETECTION OF PD-L1 IN CEREBROSPINAL FLUID OF LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS BASED ON THINPREP CYTOLOGY
HK40087642A (zh) 诊断癌症和确定癌症患者的总体生存和无病生存的方法

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240731